1 January 2017 in Solvent Extraction Research and Development, Japan
In general, dewatering of plant tissues (such as vegetables) and food materials is achieved by heating. In order to prevent the degradation of biologically active components in plant materials, the dewatering process should be carried out at low temperature. Therefore, in the present study, we attempted to develop a simple protocol for dewatering cryo-preserved plant tissues using liquefied dimethyl ether (DME). Prior to dewatering from frozen plant materials, we have examined the efficiency of liquefied DME for cryogenic removal of water from ice cubes. Here, lemon peel residue (consisting of flavedo and albedo) was chosen as the model plant material for dewatering and concomitant extractions of water-soluble components such as ascorbate and citric acid and hydrophobic components, chiefly, essential oils (EOs). By focusing on the exploitation of unused resources after food processing, the juice extraction residues from lemon fruits (lemon peels) were used as the starting materials. The yield of vitamin C (VC) extracted from the peel tissues derived from a single lemon fruit exceeded the amount of VC found in the manually press-extracted juice from a single lemon fruit. The major components in DME-extracted crude lemon EOs were determined and quantified with gas chromatography-mass spectrometry (GC-MS) and gas chromatography-flame ionization detector (GC-FID) to be limonene (40.4%, w/w), β-pinene (10.4%, w/w), and γ-terpinene (6.9 %, w/w).
10 June 2025 in International Journal of Rheumatic Diseases
Objectives: The aim of this study was to identify the risk factors for Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) and to recommend appropriate disease‐modifying antirheumatic drug (DMARD) selection for those at high risk of developing PCP. Methods: We conducted a retrospective review of patients with RA who were treated with methotrexate or biologic and targeted synthetic DMARDs (b/tsDMARDs). Patients with no chest computed tomography data or those receiving prophylactic sulfamethoxazole–trimethoprim, atovaquone, or inhaled pentamidine were excluded. Results: Among 554 patients who met the inclusion and exclusion criteria, 16 developed PCP. Multivariate logistic analysis revealed interstitial pneumonia as a significant risk factor for PCP (odds ratio: 4.53, 95% confidence interval: 1.51–13.12), whereas salazosulfapyridine (SASP) use was associated with a reduced risk (odds ratio: 0.11, 95% confidence interval: 0.00–0.81). A Kaplan–Meier analysis comparing the cumulative incidence of PCP between propensity score‐matched SASP users and nonusers further demonstrated that SASP use reduced the risk of developing PCP. Conclusion: Patients with RA complicated by interstitial pneumonia are at a higher risk of developing PCP. Although methotrexate and b/tsDMARDs do not increase the risk of developing PCP, SASP may potentially reduce the risk. A prospective study is warranted to investigate the efficacy and safety of SASP in patients with RA at high risk for PCP.
28 April 2021 in Respirology Case Reports
Adult‐onset Still's disease (AOSD) is a rare inflammatory autoimmune disorder characterized by fever, skin rash, and arthralgia. Pulmonary artery hypertension (PAH) rarely occurs with AOSD and has not been reported in the absence of typical symptoms of AOSD. A 33‐year‐old woman was admitted to our hospital with dyspnoea on exertion. Although she had not had symptoms of AOSD for 18 months before her admission, she presented with gradually progressing PAH. Because she had no typical symptoms of AOSD, she was treated with pulmonary vasodilators. However, her PAH did not improve. At one month after vasodilator treatment, she developed a high fever with elevation of ferritin. We determined that her AOSD had relapsed. Immunosuppressants were started and both her AOSD and PAH quickly improved. PAH may develop in the absence of typical symptoms of AOSD and immunosuppressants may be effective in such a case.
25 August 2026 in European Heart Journal - Cardiovascular Pharmacotherapy
Aims: Hydroxychloroquine (HCQ) is commonly prescribed for malaria and autoimmune diseases, yet its potential for cardiotoxicity remains under-recognized. The objective of this study was to investigate the clinical and experimental features of HCQ-associated cardiotoxicity. Methods and results: We retrospectively analysed 261 HCQ-treated patients, assessing cardiac adverse events and electrocardiographic intervals. Endomyocardial biopsy specimens were examined via transmission electron microscopy. To explore potential pathophysiological correlates, human-induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) were exposed to HCQ, and electrophysiological, ultrastructural, contractile and autophagy-related responses were evaluated. Hydroxychloroquine was discontinued in 14 patients, including 3 patients with clinically significant cardiotoxicity manifesting as heart failure or an isolated conduction abnormality (1.1% of the cohort). QTc intervals increased from a median of 413 ms [interquartile range (IQR), 399–426 ms] pre-treatment to 421 ms (IQR, 407–440 ms) on-treatment (P = 0.003), indicating a modest but statistically significant change. PR interval also increased modestly from 148 ms (IQR, 140–163 ms) to 150 ms (IQR, 142–168 ms) (P = 0.041). In vitro, HCQ exposure in hiPSC-CMs prolonged corrected field potential duration (P = 0.013) and induced arrhythmic activity. Motion analysis demonstrated a reduced peak relaxation velocity (P < 0.01), with concomitant attenuation of contractile function. Transmission electron microscopy showed lamellar inclusions consistent with myelin-like bodies. Hydroxychloroquine exposure significantly increased autophagy-related protein levels, suggesting impaired autophagic degradation. These cellular phenotypes were consistent with clinical manifestations of HCQ-associated electrical abnormalities and cardiomyopathy. Conclusion: Hydroxychloroquine therapy was associated with electrical abnormalities and cardiomyopathy. Experimental findings in hiPSC-CMs recapitulated key clinical features and provided biological support for the clinical observations.
27 March 2026 in ACR Open Rheumatology